NUCB2 and breast cancer: Additionally, upregulated lncRNA XIST in malignant lymph nodes was in alliance with further studies, postulating the candidate biomarker role of upregulated CD-169 (46), NUCB2 (47), and P-cadherin (48) in BC patients malignant lymph nodes.